Variant | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AF EXOME | AF GENOME | Disease | Disease Class | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
0.882 | 0.040 | 12 | 68820362 | missense variant | G/A | snv |
|
Neoplasms | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||||
|
0.882 | 0.040 | 12 | 68820362 | missense variant | G/A | snv |
|
Neoplasms | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||||
|
0.882 | 0.040 | 12 | 68820362 | missense variant | G/A | snv |
|
Neoplasms | 0.010 | 1.000 | 1 | 2015 | 2015 | ||||||||
|
0.925 | 0.080 | 12 | 68808776 | intron variant | G/C | snv | 2.3E-02 |
|
Neoplasms | 0.050 | 1.000 | 5 | 2012 | 2019 | |||||||
|
0.925 | 0.080 | 12 | 68808776 | intron variant | G/C | snv | 2.3E-02 |
|
Neoplasms | 0.050 | 1.000 | 5 | 2012 | 2019 | |||||||
|
0.925 | 0.080 | 12 | 68808776 | intron variant | G/C | snv | 2.3E-02 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
0.925 | 0.080 | 12 | 68808776 | intron variant | G/C | snv | 2.3E-02 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||||
|
12 | 68808835 | intron variant | T/A | snv | 4.8E-02 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||||||
|
12 | 68808835 | intron variant | T/A | snv | 4.8E-02 |
|
Neoplasms | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||||||
|
0.925 | 0.080 | 12 | 68839568 | missense variant | A/G | snv | 7.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | < 0.001 | 1 | 2016 | 2016 | |||||||
|
0.925 | 0.080 | 12 | 68839568 | missense variant | A/G | snv | 7.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.010 | < 0.001 | 1 | 2016 | 2016 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.100 | 0.733 | 15 | 2007 | 2017 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.100 | 0.733 | 15 | 2007 | 2017 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms | 0.100 | 0.900 | 10 | 2006 | 2017 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms | 0.050 | 1.000 | 5 | 2007 | 2019 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms | 0.050 | 1.000 | 5 | 2009 | 2014 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Digestive System Diseases; Neoplasms | 0.050 | 0.800 | 5 | 2008 | 2017 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms | 0.040 | 1.000 | 4 | 2007 | 2019 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms; Respiratory Tract Diseases | 0.030 | 1.000 | 3 | 2008 | 2014 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms; Skin and Connective Tissue Diseases | 0.030 | 1.000 | 3 | 2010 | 2014 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nutritional and Metabolic Diseases | 0.020 | 1.000 | 2 | 2011 | 2016 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | 0.020 | 0.500 | 2 | 2007 | 2011 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Digestive System Diseases; Neoplasms | 0.020 | 0.500 | 2 | 2011 | 2015 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Hemic and Lymphatic Diseases | 0.020 | 0.500 | 2 | 2012 | 2015 | |||||||
|
0.550 | 0.720 | 12 | 68839311 | missense variant | C/G | snv | 4.0E-06 |
|
Neoplasms; Female Urogenital Diseases and Pregnancy Complications | 0.020 | 1.000 | 2 | 2013 | 2014 |